Background: Evaluation and location of the approaches is the key step of medical thoracoscopy. The previous standard for the step in many countries is artificial pneumothorax (AP). Recently, thoracic ultrasound (TU) has been considered as one of the choices for the development of technology. While there was a lack of data in investigating the complications of medical thoracoscopy locating approach with AP comparing TU. Methods: A total of 108 patients who underwent medical thoracoscopy were retrospectively observed in Peking University First Hospital from January 2011 to April 2017, including 92 patients of the AP group and 16 patients of the TU group. Propensity score matching (PSM) was used to balance the covariance between the two groups. And the complications of the procedures between the groups were compared. Results: Before PSM, there was one unbalanced covariates in the two groups. The overall complication rate was 7.6% (7/92) in the AP group, comparing 6.2% (1/16) in the TU group. There was no significant difference between the two groups (P=0.848). After balancing the covariate with 2:1 matched, the overall complication rate was 9.4% (3/32) in the AP group, comparing 6.2% (1/16) in the TU group. There was still no significant difference between the two groups (P=0.712). Conclusions: TU is a locating approach method which does not increase the complication rate comparing with AP. And it could be a good choice in medical thoracoscopy.
Background
Asthma is a common chronic airway inflammatory disease. Exacerbations of asthma not only accelerate the progression of the disease but also increase the incidence of hospitalization and death. Studies have shown that air pollution is a high-risk factor for asthma exacerbations. However, few treatment strategies have been recommended to reduce the risk of severe air pollution-related asthma exacerbations.
Methods/design
This is a single-centre, prospective, randomized and standard treatment parallel control clinical trial. Seventy-two asthma patients in the nonexacerbation stage according to GINA guidelines 2017 will be recruited and randomized into the rescue intervention strategy (RIS) group and control group. Original treatments for the participants will include no use of inhaled medicine, the use of short-acting β-agonists (SABA) on demand or the use of budesonide/formoterol (160 μg/4.5 μg/dose, 1–2 dose/time, b.i.d.). The rescue intervention strategy for the RIS group will be budesonide/formoterol plus the original treatment until the severe pollution ends (air quality index, AQI < 200). The control group will maintain the original treatment. The follow-up observation period will last 1 year. The primary outcome is the frequency of asthma exacerbations per year. Secondary outcomes include the mean number of unplanned outpatient visits, emergency visits, hospitalizations, medical costs and mortality caused by asthma exacerbations per patient per year.
Discussion
The results of this trial will provide a novel strategy to guide clinical practice in decreasing the risk of asthma exacerbations under severe air pollution.
Trial registration
ChiCTR ChiCTR1900026757. Registered on 20 October 2019—retrospectively registered
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.